Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 1, 2000, Pages 3-28

  Bartsch, Helmut ^a   Nair, Urmila ^a   Risch, Angela ^a   Rojas, Margarita ^a   Wikman, Harriet ^a   Alexandrov, Kroum ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; REVIEW; SMOKING; TOBACCO; URINARY TRACT CANCER;

BREAST NEOPLASMS; CARCINOGENS; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 0033984936     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (183)

1. Caporaso, N., and Goldstein, A. Cancer genes - single and susceptibility -exposing the difference. Pharmacogenetics, 5: 59-63, 1995.
2. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A. M. Kadlubar, F. F., Landi, M. T., Malaveille, C., Shields, P. G., Skipper, P., Talaska, G., and Tannenbaum, S. R. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature (Lond.), 369: 154-156, 1994.
3. Vineis, P. Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Int. J. Cancer, 71: 1-3, 1997.
4. Bartsch, H., and Hietanen, E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ. Health Perspect., 104 (Suppl. 3): 569-577, 1996.
5. Doll, R. Uncovering the risks of smoking: historical perspective. Stat. Meth. Med. Res., 7: 87-117, 1998.
6. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Laughlin, R., Nemoto, T., Michalek, A. M., Harrington, A., Ford, T. D., and Shields, P. G. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res., 55: 3483-3485, 1995.
7. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Michalek, A. M., Laughlin, R., Nemoto, T., Gillenwater, K. A., and Shields, P. G. Cigarette smoking, N-acetyltransferase-2 genetic polymorphisms, and breast cancer risk. J. Am. Med. Assoc., 276: 1494-1501, 1996.
8. Hoffmann, D., and Hecht, S. S. Advances in tobacco carcinogenesis. In: C. S. Cooper and P. L. Grover (eds.), Chemical Carcinogenesis and Mutagenesis I, pp. 63-103. Berlin: Springer, 1990.
9. Hecht, S. S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst., 91: 1194-1210, 1999.
10. McClellan, R. O. Tobacco-specific N-nitrosamines. Recent Adv. Crit. Rev. Toxicol., 26: 119-253, 1996.
11. Bergen, A. W., and Caporaso, N. Cigarette smoking. J. Natl. Cancer Inst., 91: 1365-1375, 1999.
12. Coles, B., and Ketterer, B. The role of glutathione transferase in chemical carcinogenesis. CRC Crit. Rev. Biochem. Mol. Biol., 25: 47-70, 1990.
13. Alexandrov, K., Rojas, M., Geneste, O., Castegnaro, M., Camus, A. M., Petruzzelli, S., Giuntini, C., and Bartsch, H. An improved fluorometric assay for dosimetry of benzo[a]pyrene diol-epoxide-DNA adducts in smoker's lung: comparison with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res., 52: 6248-6253, 1992.
14. Kriek, E., Rojas, M., Alexandrov, K., and Bartsch, H. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat. Res., 400: 215-231, 1998.
15. Hecht, S. S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res., 424: 127-142, 1999.
16. Bartsch, H., Malaveille, C., Friesen, M., Kadlubar, F. F., and Vineis, P. Smoking and urinary bladder cancer: molecular dosimetry studies in smokers of black and blond tobacco implicate aromatic amines. Eur. J. Cancer, 29A: 1199-1207, 1993.
17. Brockmöller, J., Cascorbi I., Kerb, R., Sachse, C., and Roots, I. Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol. Lett., 102-103: 173-183, 1998.
18. Chung, F-L., Chen, H-J. C., and Nath, R. G. Lipid peroxidation as a potential endogenous source for the formation of exocyclic DNA adducts. Carcinogenesis (Lond.), 17: 2105-2111, 1996.
19. Nair, J., Barbin, A., Velic, I., and Bartsch, H. Etheno DNA-base adducts from endogenous reactive species. Mutat. Res., 424: 59-69, 1999.
20. 2-Propanodeoxyguanosine adducts: potential new biomarkers of smoking-induced DNA damage in human oral tissue. Cancer Res., 58: 581-584, 1998.
21. Nair, J., Oshima, H., Nair, U. J., and Bartsch, H. Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users. Crit. Rev. Toxicol., 26: 149-162, 1996.
22. Nair, U. J., Nair, J., Mathew, B., and Bartsch, H. Glutathione S-transferase M1 and T1 null genotypes as risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers. Carcinogenesis (Lond.), 5: 743-748, 1999.
23. González, F. J. The role of carcinogen-metabolizing enzyme polymorphism in cancer susceptibility. Reprod. Toxicol., 11: 397-412, 1997.
24. Puga, A., Nebert, D. W., McKinnon, R. A., and Menon, A. G. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit. Rev. Toxicol., 27: 199-222, 1997.
25. Guengerich, F. P., and Shimada, T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res., 400: 201-213, 1998.
26. Cascorbi, I., Brockmöller, J., and Roots, I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res., 56: 4965-4969, 1996.
27. Nebert, D. W., McKinnon, R. A., and Puga, A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol., 15: 273-280, 1996.
28. Kawajiri, K., Watanabe, J., Eguchi, H., Nakachi, K., Kiyohara, C., and Hayashi, S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics, 5: 151-158, 1995.
29. Micka, J., Milatovich, A., Menon, A., Grabowski, G. A., Puga, A., and Nebert, D. W. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics, 7: 95-101, 1997.
30. Kellerman, G., Shaw, C. R., and Luyten-Kellerman, M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. Engl. J. Med., 289: 934-937, 1973.
31. Peterson, D. D., McKinney, C. E., Ikeya, K., Smith, H. H., Bale, A. E., McBride, O. W., and Nebert, D. W. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am. J. Hum. Genet., 48: 720-725, 1990.
32. Landi, M. T., Bertazzi, P. A., Shields, P. G., Clark, Lucier, G. W., Garte, S. J., Cosma, G., and Caporaso, N. E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics, 4: 242-246, 1994.
33. Zhang, Z-Y., Fasco, M. J., Huang, L., Guengerich, P., and Kaminsky, L. S. Characterization of purified human recombinant cytochrome P4501A1-lle462 and Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res., 56: 3926-3933, 1996.
34. Persson, I., Johansson I., and Ingelman-Sundberg, M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun., 231: 227-230, 1997.
35. Mooney, L. V., Bell, D. A., Santella, R. M., Van Bennekum, A. M., Ottman, R., Paik, M., Blaner, W. S., Lucier, G. W., Covey, L., Young, T-L., Cooper, T. B., Glassman, H., and Perera, F. P. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis (Lond.), 18: 503-509, 1997.
36. Whyatt, R. M., Bell, D. A., Jedrychowski, W., Santella, R. M., Garte, S. J., Cosma, G., Manchester, D. K., Young, T-L., Cooper, T. B., Ottman, R., and Perera, F. P. Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype. Carcinogenesis (Lond.), 8: 1389-1392, 1998.
37. Vaury, C., Laine, R., Noguiez, P., de Coppet, P., Jaulin, C., Praz, F., Pompon, D., and Amor-Guéret, M. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res., 55: 5520-5523, 1995.
38. Bartsch, H. DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Mutat. Res., 340: 67-69, 1996.
39. Rojas, M., Alexandrov, K., Cascorbi, I., Brockmöller, J., Likhachev, A., Pozharisski, K., Bouvier, G., Auburtin, G., Mayer, L., Koop-Schneider, A., Roots, I., and Bartsch, H. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from subjects with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics, 8: 109-118, 1998.
40. Romkes, M., White, C., Johnson, J., Eibling, D., Landreneau, R., and Branch, R. Expression of cytochrome P450 mRNA in human lung, head and neck tumours, and normal adjacent tissues. Proc. Am. Assoc. Cancer Res., 37: 105, 1996.
41. Lazarus, P., Sheikh, S. N., Ren, Q., Schantz, S. P., Stern, J. C., Richie, J. P., Jr., and Park, J. Y. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis (Lond.), 19: 509-514, 1998.
42. Murray, G. I., Taylor, V. E., McKay, J. A., Weaver, R. J., Ewen, S. W., Melvin, W. T., and Burke, M. D. Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int. J. Exp. Pathol., 76: 271-276, 1995.
43. Bailey, L. R., Roodi, N., Verrier, C. S., Yee, C. J., Dupont, W. D., and Parl, F. F. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res., 58: 65-70, 1998.
44. Mace, K., Bowman, E. D., Vautravers, P., Shields, P. G., Harris, C. C., and Pfeifer, A. M. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur. J. Cancer, 34: 914-920, 1998.
45. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshima, M., Funayama, M., and Kamataki, T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene effect on the CYP1A2 inducibility in humans. J. Biochem., 125: 803-808, 1999.
46. MacLeod, S., Tang, Y-M., Yokoi, T., Kamataki, T., Doublin, S., Lawson, B., Massengill, J., Kadlubar, F., and Lang, N. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc. Am. Assoc. Cancer Res., 39: 396, 1998.
47. Sachse, C., Brockmöller, J., Bauer, S., and Roots, I. Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol., 47: 445-449, 1999.
48. Bartsch, H., Rojas, M., Alexandrov, K., Camus, A-M., Castegnaro, M., Malaveille, C., Anttila, S., Hirvonen, K., Husgafvel-Pursiainen, K., Hietanen, E., and Vainio, H. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics, 5: 884-890, 1995.
49. MacLeod, S., Sinha, R., Kadlubar, F. F., and Lang, N. P. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res., 376: 135-142, 1997.
50. Yu, M., Ross, R., and Chan, K. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian men in Los Angeles, California. J. Natl. Cancer Inst., 86: 712-716, 1995.
51. Bailey, L. R., Roodi, N., Dupont, W. D., and Parl, F. F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res., 58: 5038-5041, 1998.
52. Tiano, H. F., Wang, R-L., Hosokawa, M., Crespi, C., Tindall, K. R., and Langenbach, R. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis (Lond.), 15: 2859-2866, 1994.
53. Nunoya, K., Yokoi, T., Kimura, K., Inoue, K., Kodama, T., Funayama, M., Nagashima, K., Funae, Y., Green, C., Kinoshita, M., and Kamataki, T. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics, 8: 239-249, 1998.
54. Pianezza, M. L., Sellers, E. M., and Tyndale, R. F. Nicotine metabolism defect reduces smoking. Nature (Lond.), 393: 750, 1998.
55. London, S. J., Idle, J. R., Daly, A. K., and Coetzee, G. A. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet, 353: 898-899, 1999.
56. Chen, G. F., Tang, Y. M., Green, B., Lin, D. X., Guengerich, F. P., Daly, A. K., Caporaso, N. E., and Kadlubar, F. F. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics, 9: 327-332, 1999.
57. Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q. Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O., and Ingelman-Sundberg, M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett., 448: 105-110, 1999.
58. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.). 312: 169-170, 1984.
59. Daly, A. K., Brockmöller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Stehen, V. M., Wolf, C. R., and Zanger, U. M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6: 193-201, 1996.
60. Raunio, H., Hakkola, J., Hukkanen, J., Lassila, A., Päivärinta, K., Pelkonen, O., Anttila, S., Piipari, P., Boobis, A., and Edwards, R. J. Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp. Toxicol. Pathol., 51: 412-417, 1999.
61. Boustead, C., Taber, H., Idle, J. R., and Cholerton, S. CYP2D6 genotype and smoking behaviour in cigarette smokers. Pharmacogenetics, 7: 411-414, 1997.
62. Saarikoski, S. T., Sata, F., Husgafvel-Pursiainen, K., Rautalahti, M., Haukka, J., Impivaara, O., Järvisalo, J., Vainio, H., and Hirvonen, A. CYP2D6 ultrarapid metabolizer genotype as potential modifier of smoking behaviour. Pharmacogenetics, in press, 2000.
63. Legrand Andreoletti, M., Stucker, I., Marez, D., Galais, P., Cosme, J., Sabbagh, N., Spire, C., Cenee, S., Lafitte, J. J., Beaune, P., and Broly, F. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics, 8: 7-14, 1998.
64. Christensen, P. M., Gotzsche, P. C., and Brosen, K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur. J. Clin. Pharmacol., 51: 389-393, 1997.
65. Rostami Hodjegan, A., Lennard, M. S., Woods, H. F., and Tucker, G. T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics, 8: 227-238, 1998.
66. Chinegwundoh, F. I., and Kaisary, A. V. Polymorphism and smoking in bladder carcinogenesis. Br. J. Urol., 77: 672-675, 1996.
67. Villard, P. H., Seree, E. M., Re, J. L., De Meo, M., Barra, Y., Attolini, L., Dumenil, G., Catalin, J., Durand, A., and Lacarelle, B. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA. Toxicol. Appl. Pharmacol., 148: 195-204, 1998.
68. LeMarchand, L., Wilkinson, G. R., and Wilkens, L. R. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol. Biomark. Prev., 8: 495-500, 1999.
69. Watanabe, J., Hayashi, S., and Kawajiri, K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J. Biochem. (Tokyo), 116: 321-326, 1994.
70. Degawa, M., Stern, S. J., Martin, M. V., Guengerich, F. P., Fu, P. P., Ilett, K. F., Kaderlik, R. K., and Kadlubar, F. F. Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res., 54: 4915-4919, 1994.
71. Ozawa, S., Schoket, B., McDaniel L. P., Tang, Y-M., Ambrosone, C. B., Kostic, S., Vincze, I., and Kadlubar, F. F. Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases. Carcinogenesis (Lond.), 6: 991-995, 1999.
72. DeMorais, S. M. F., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., and Goldstein, J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 269: 15419-15422, 1994.
73. DeMorais, S. M. F., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., and Goldstein, J. A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Jpn. Mol. Pharmacol., 46: 594-598, 1994.
74. Patten, C. J., Smith, T. J., Friesen, M. J., Tynes, R. E., Yang, C. S., and Murphy, S. E. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N′ nitrosonornicotine α-hydroxylation by human liver microsomes. Carcinogenesis (Lond.), 18: 1623-1630, 1997.
75. Peyronneau, M. A., Renaud, J. P., Jaouen, M., Urban, P., Cullin, C., Pompon, D., and Mansuy, D. Expression in yeast of three allelic cDNAs coding for human liver P-450 3A4. Different stabilities, binding properties and catalytic activities of the yeast-produced enzymes. Eur. J. Biochem., 218: 355-361, 1993.
76. Feigelson, H. S., Shames, L. S., Pike, M. C., Coetzee, G. A., Stanczyk, F. Z., and Henderson, B. E. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res., 58: 585-587, 1998.
77. Polymeropoulos, M. H., Xiao, H., Rath, D. S., and Merril, C. R. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res., 19: 195, 1991.
78. Kihara, M., Kihara, M., and Noda, K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis (Lond.), 16: 2331-2336, 1995.
79. Mollerup, S., Ryberg, D., Hewer, A., Phillips, D. H., and Haugen, A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res., 59: 3317-3320, 1999.
80. Kawajiri, K., Eguchi, H., Nakachi, K., Sekiya, T., and Yamamoto, M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res., 56: 72-76, 1996.
81. Goto, M., Yoneda, S., Yamamoto, M., and Kawajiri, K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione 5-transferase genes in patients with non-small cell lung cancer. Cancer Res., 6: 3725-3730, 1996.
82. Bartsch, H., Hietanen, E., Petruzzelli, S., Giuntini, C., Saracci, R., Mussi, A., and Angeletti, C. A. Possible prognostic value of pulmonary Ah locus-linked enzymes in patients with tobacco-related lung cancer. Int. J. Cancer, 46: 185-188, 1990.
83. IARC. Application of biomarkers in cancer epidemiology. In: P. Toniolo, P. Boffetta, D. Shuker, N. Rothman, B. Hulka, and N. Pearce (eds.). IARC Sci. Publ., Vol. 142, pp. 1-318, 1997.
84. IARC. Metabolic polymorphisms and susceptibility to cancer. In: P. Vineis, M. Malats, M. Lang, A. d'Errico, N. Caporaso, J. Cuzick, and P. Boffetta (eds.). IARC Sci. Publ., Vol. 148, pp. 1-510, 1999.
85. Kaiser, J. Environment institute lays plans for gene hunt. Science (Washington DC), 278: 569-570, 1997.
86. Nebert, D. W., Ingelman-Sundberg, M., and Daly, A. K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab. Rev., 31: 467-487, 1999.
87. Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N., and Watanabe, J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett., 263: 131-133, 1990.
88. Tefre, T., Ryberg, D., Haugen, A., Nebert, D. W., Skaug, V., Brogger, A., and Borresen, A. L. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics, 1: 20-25, 1991.
89. Nakachi, K., Imai K., Hayaschi, S. I., Watanabe, J., and Kawajiri, K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res., 51: 5177-5180, 1991.
90. Hayashi, S., Watanabe, J., and Kawajiri, K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes. Jpn. J. Cancer Res., 83: 866-870, 1992.
91. Hirvonen, A., Husgafvel Pursiainen, K., Anttila, S., Karjalainen, A., Sorsa, M., and Vainio, H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics, 2: 259-263, 1992.
92. Hirvonen, A., Husgafvel Pursiainen, K., Karjalainen, A., Anttila, S., and Vainio, H. Point-mutational MspI and lle-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomark. Prev., 1; 485-489, 1992.
93. Hirvonen, A., Husgafvel Pursiainen, K., Anttila, S., Karjalainen, A., and Vainio, H. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Environ. Health Perspect., 101 (Suppl. 3): 109-112, 1993.
94. Shields, P. G., Caporaso, N. E., Falk, R. T., Sugimura, H., Trivers, G. E., Trump, B. F., Hoover, R. N., Weston, A., and Harris, C. C. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol. Biomark. Prev., 2: 481-485, 1993.
95. Nakachi, K., Imai, K., Hayashi, S., and Kawajiri, K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res., 53: 2994-2999, 1993.
96. Alexandrie, A. K., Sundberg, M. I., Seidegard, J., Tornling, G., and Rannug, A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis (Lond.), 15: 1785-1790, 1994.
97. Kelsey, K. T., Wiencke, J. K., and Spitz, M. R. A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis (Lond.), 15: 1121-1124, 1994.
98. Okada, T., Kawashima, K., Fukushi, S., Minakuchi, T., and Nishimura, S. Association between a cytochrome P450 CYP1A1 genotype and incidence of lung cancer. Pharmacogenetics, 4: 333-340, 1994.
99. Sugimura, H., Hamada, G. S., Suzuki, I., Iwase, T., Kiyokawa, E., Kino, I., and Tsugane, S. CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics. Spec. No. 5: 145-148, 1995.
100. Hamada, G. S., Sugimura, H., Suzuki, I., Nagura, K., Kiyokawa, E., Iwase, T., Tanaka, M., Takahashi, T., Watanabe, S., Kino, I., and Tsugane, S. The heme-binding region polymorphism of cytochrome P450IA1 (CypIA1), rather than the Rsal polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol. Biomark. Prev., 4: 63-67, 1995.
101. Sugimura, H., Suzuki, I., Hamada, G. S., Iwase, T., Takahashi, T., Nagura, K., Iwata, H., Watanabe, S., Kino, I., and Tsugane, S. Cytochrome P-450 1A1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol. Biomark. Prev., 3: 145-148, 1994.
102. London, S. J., Daly, A. K., Fairbrother, K. S., Holmes, C., Carpenter, C. L., Navidi, W. C., and Idle, J. R. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism [see comments]. Cancer Res., 55: 6035-6037, 1995.
103. Drakoulis, N., Cascorbi, I., Brockmöller, J., Gross, C. R., and Roots, I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon 7 mutation (4889 A to G) and a T to C mutation in the 3′-flanking region. Clin. Investig., 72: 240-248, 1994.
104. Jacquet, M., Lambert, V., Baudoux, E., Muller, M., Kremers, P., and Gielen, J. Correlation between P450 CYP1A1 inducibility. MspI genotype and lung cancer incidence. Eur. J. Cancer, 32A: 1701-1706, 1996.
105. Xu, X., Kelsey, K. T., Wiencke, J. K., Wain, J. C., and Christiani, D. C. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 5: 687-692, 1996.
106. Garcia Closas, M., Kelsey, K. T., Wiencke, J. K., Xu, X., Wain, J. C., and Christiani, D. C. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes Control, 8: 544-553, 1997.
107. Ishibe, N., Wiencke, J. K., Zuo, Z. F., McMillan, A., Spitz, M., and Kelsey, K. T. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol. Biomark. Prev., 6: 1075-1080, 1997.
108. Bouchardy, C., Wikman, H., Benhamou, S., Hirvonen, A., Dayer, P., and Husgafvel-Pursiainen, K. CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers, 2: 131-134, 1997.
109. Le Marchand, L., Sivaraman, L., Pierce, L., Seifried, A., Lum, A., Wilkens, L. R., and Lau, A. F. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res., 58: 4858-4863, 1998.
110. Taioli, E., Ford, J., Trachman, J., Li, Y., Demopoulos, R., and Garte, S. Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis (Lond.), 19: 813-817, 1998.
111. Taioli, E., Crofts, F., Trachman, J., Demopoulos, R., Toniolo, P., and Garte, S. J. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res., 55: 472-473, 1995.
112. Sugimura, H., Wakai, K., Genka, K., Nagura, K., Igarashi, H., Nagayama, K., Ohkawa, A., Baba, S., Morris, B. J., Tsugane, S., Ohno, Y., Gao, C., Li, Z., Takezaki, T., Tajima, K., and Iwamasa, T. Association of IIe462Val (exon 7) polymorphism of cytochrome P450 1A1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol. Biomark. Prev., 7: 413-417, 1998.
113. Kiyohara, C., Nakanishi, Y., Inutsuka, A., Takayama, K., Hara, N., Motohiro, A., Tanaka, K., Kono, S., and Hirohata, T. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics, 8: 315-323, 1998.
114. Persson, I., Johansson, I., Lou, Y. C., Yue, Q. Y., Duan, L. S., Bertilsson, L., and Ingelman Sundberg, M. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int. J. Cancer, 81: 325-329, 1999.
115. Hong, Y. S., Chang, J. H., Kwon, O. J., Ham, Y. A., and Choi, J. H. Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients. Exp. Mol. Med., 30: 192-198, 1998.
116. Smith, C. A., Moss, J. E., Gough, A. C., Spurr, N. K., and Wolf, C. R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ. Health Perspect., 98: 107-112, 1992.
117. Wolf, C. R., Dale Smith, C. A., Gough, A. C., Moss, J. E., Vallis, K. A., Howard, G., Garey, F. J., Mills, K., McNee, W., Carmichael, J., and Spurr, N. K. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis (Lond.), 13: 1035-1038, 1992.
118. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Pelkonen, O., and Vainio, H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics, 3: 19-27, 1993.
119. Agundez, J. A., Martinez, C., Ladero, J. M., Ledesma, M. C., Ramos, J. M., Martin, R., Rodriguez, A., Jara, C., and Benitez, J. Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin. Pharmacol. Ther., 55: 10-14, 1994.
120. Tefre, T., Daly, A. K., Armstrong, M., Leathart, J. B., Idle, J. R., Brogger, A., and Borresen, A. L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics, 4: 47-57, 1994.
121. Dolzan, V., Rudolf, Z., and Breskvar, K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis (Lond.), 16: 2675-2678, 1995.
122. El Zein, R., Zwischenberger, J. B., Wood, T. G., Abdel Rahman, S. Z., Brekelbaum, C., and Au, W. W. Combined genetic polymorphism and risk for development of lung cancer. Mutat. Res., 381: 189-200, 1997.
123. El Zein, R., Conforti Froes, N., and Au, W. W. Interactions between genetic predisposition and environmental toxicants for development of lung cancer. Environ. Mol. Mutagen., 30: 196-204, 1997.
124. London, S. J., Daly, A. K., Leathart, J. B., Navidi, W. C., Carpenter, C. C., and Idle, J. R. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis (Lond.), 18: 1203-1214, 1997.
125. Legrand, M., Stucker, I., Marez, D., Sabbagh, N., Lo Guidice, J. M., and Broly, F. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. Carcinogenesis (Lond.), 17: 2267-2269, 1996.
126. Stucker, I., Cosme, J., Laurent, P., Cenee, S., Beaune, P., Bignon, J., Depierre, A., Milleron, B., and Hemon, D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis (Lond.), 16: 2759-2764, 1995.
127. Shaw, G. L., Falk, R. T., Frame, J. N., Weiffenbach, B., Nesbitt, J. C., Pass, H. I., Caporaso, N. E., Moir, D. T., and Tucker, M. A. Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomark. Prev., 7: 215-219, 1998.
128. Shaw, G. L., Weiffenbach, B., Falk, R. T., Frame, J. N., Issaq, H. J., Moir, D. T., and Caporaso, N. Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls. Lung Cancer, 17: 61-68, 1997.
129. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R., and Watanabe, M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res., 82: 254-256, 1991.
130. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Ishioka, C., Kanamaru, R., Sagami, I., and Watanabe, M. Human cytochrome P450IIE1 gene: DraI polymorphism and susceptibility to cancer. Tohoku J. Exp. Med., 168: 113-117, 1992.
131. Uematsu, F., Ikawa, S., Kikuchi, H., Sagami, I., Kanamaru, R., Abe, T., Satoh, K., Motomiya, M., and Watanabe, M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics, 4: 58-63, 1994.
132. Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., Weston, A., and Harris, C. C. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res., 52: 6712-6715, 1992.
133. Hirvonen, A., Husgafvel Pursiainen, K., Anttila, S., Karjalainen, A., and Vainio, H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis (Lond.), 14: 85-88, 1993.
134. Persson, I., Johansson, I., Bergling, H., Dahl, M. L., Seidegard, J., Rylander, R., Rannug, A., Hogberg, J., and Sundberg, M. I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett., 319: 207-211, 1993.
135. Kato, S., Shields, P. G., Caporaso, N. E., Sugimura, H., Trivers, G. E., Tucker, M. A., Trump, B. F., Weston, A., and Harris, C. C. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomark. Prev., 3: 515-518, 1994.
136. Watanabe, J., Yang, J. P., Eguchi, H., Hayashi, S., Imai, K., Nakachi, K., and Kawajiri, K. An RsaI polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn. J. Cancer Res., 86: 245-248, 1995.
137. London, S. J., Daly, A. K., Cooper, J., Carpenter, C. L., Navidi, W. C., Ding, L., and Idle, J. R. Lung cancer risk in relation to the CYP2E1 RsaI genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics, 6: 151-158, 1996.
138. Oyama, T., Kawamoto, T., Mizoue, T., Sugio, K., Kodama, Y., Mitsudomi, T., and Yasumoto, K. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer in relation to p53 gene mutation. Anticancer Res., 17: 583-587, 1997.
139. El Zein, R. A., Zwischenberger, J. B., Abdel Rahman, S. Z., Sankar, A. B., and Au, W. W. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett., 112: 71-78, 1997.
140. Wu, X., Shi, H., Jiang, H., Kemp, B., Hong, W. K., Delclos, G. L., and Spitz, M. R. Associations between cytochrome P4502E1 genotype, mutagen sensitiv ty, cigarette smoking and susceptibility to lung cancer. Carcinogenesis (Lond.). 18: 967-973, 1997.
141. Wu, X., Amos, C. I., Kemp, B. L., Shi, H., Jiang, H., Wan, Y., and Spitz, M. R. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol. Biomark. Prev., 7: 13-18, 1998.
142. London, S. J., Daly, A. K., Leathart, J. B., Navidi, W. C., and Idle, J. R. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County. California. Pharmacogenetics, 6: 527-533, 1996.
143. London, S. J., Sullivan Klose, T., Daly, A. K., and Idle, J. R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics, 7: 401-404, 1997.
144. Tsuneoka, Y., Fukushima, K., Matsuo, Y., Ichikawa, Y., and Watanabe, Y. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci., 59: 1711-1715, 1996.
145. Lucas, D., Menez, C., Floch, F., Gourlaouen, Y., Sparfel, O., Joannet, I., Bodenez, P., Jezequel, J., Gouerou, H., Berthou, F., Bardou, L. G., and Menez, J. F. Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians. Alcohol Clin. Exp. Res., 20: 1033-1037, 1996.
146. Park, J. Y., Muscat, J. E., Ren, Q., Schantz, S. P., Harwick, R. D., Stern, J. C., Pike, V., Richie, J. P., Jr., and Lazarus, P. CYP1A1 and CSTM1 polymorphisms and oral cancer risk [published erratum appears in Cancer Epidemiol. Biomark. Prev., 6: 1108, 1997]. Cancer Epidemiol. Biomark. Prev., 6: 791-797, 1997.
147. Matthias, C., Bockmuhl, U., Jahnke, V., Jones, P. W., Hayes, J. D., Alldersea, J., Gilford, J., Bailey, L., Bath, J., Worrall, S. F., Hand, P., Fryer, A. A., and Strange, R. C. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics, 8: 91-100, 1998.
148. Oude Ophuis, M. B., van Lieshout, E. M., Roelofs, H. M., Peters, W. H., and Manni, J. J. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer (Phila.), 82: 936-943, 1998.
149. Morita, S., Yano, M., Tsujinaka, T., Akiyama, Y., Taniguchi, M., Kaneko, K., Miki, H., Fujii, T., Yoshino, K., Kusuoka, H., and Monden, M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int. J. Cancer, 80: 685-688, 1999.
150. Tanimoto, K. S., Hayashi, S., Yoshiga, K., and Ichikawa, T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol., 35: 191-196, 1999.
151. Gonzalez, M. V., Alvarez, V., Pello, M. F., Menendez, M. J., Suarez, C., and Coto, E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J. Clin. Pathol., 51: 294-298, 1998.
152. Worrall, S. F., Corrigan, M., High, A., Starr, D., Matthias, C., Wolf, C. R., Jones, P. W., Hand, P., Gilford, J., Farrell, W. E., Hoban, P., Fryer, A. A., and Strange, R. C. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics, 8: 433-439, 1998.
153. Hung, H. C., Chuang, J., Chien, Y. C., Chern, H. D., Chiang, C. P., Kuo, Y. S., Hildesheim, A., and Chen, C. J. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1: environmental factors and risk of oral cancer. Cancer Epidemiol. Biomark. Prev., 6: 901-905, 1997.
154. Hori, H., Kawano, T., Endo, M., and Yuasa, Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J. Clin. Gastroenterol., 25: 568-575, 1997.
155. Morita, S., Yano, M., Shiozaki, H., Tsujinaka, T., Ebisui, C., Morimoto, T., Kishibuti, M., Fujita, J., Ogawa, A., Taniguchi, M., Inoue, M., Tamura, S., Yamazaki, K., Kikkawa, N., Mizunoya, S., and Monden, M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer, 71: 192-195, 1997.
156. Nimura, Y., Yokoyama, S., Fujimori, M., Aoki, T., Adachi, W., Nasu, T., He, M., Ping, Y. M., and Iida, F. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer (Phila.), 80: 852-857, 1997.
157. Van Lieshout, E. M., Roelofs, H. M., Dekker, S., Mulder, C. J., Wobbes, T., Jansen, J. B., and Peters, W. H. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res., 59: 586-589, 1999.
158. Lin, D. X., Tang, Y. M., Peng, Q., Lu, S. X., Ambrosone, C. B., and Kadlubar, F. F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione 5-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol. Biomark. Prev., 7: 1013-1018, 1998.
159. Katoh, T., Inatomi, H., Nagaoka, A., and Sugita, A. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis (Lond.), 16: 655-657, 1995.
160. Brockmöller, J., Cascorbi, I., Kerb, R., and Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56: 3915-3925, 1996.
161. Spurr, N. K., Gough, A. C., Chinegwundoh, F. I., and Smith, C. A. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin. Chem., 41: 1864-1869, 1995.
162. Anwar, W. A., Abdel Rahman, S. Z., El Zein, R. A., Mostafa, H. M., and Au, W. W. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis (Lond.), 17: 1923-1929, 1996.
163. Farker, K., Lehmann, M. H., Oelschlagel, B., Haerting, J., Hoffmann, A., Janitzky, V., and Schubert, J. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp. Toxicol. Pathol., 50: 425-431, 1998.
164. Rebbeck, T. R., Rosvold, E. A., Duggan, D. J., Zhang, J., and Buetow, K. H. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol. Biomark. Prev., 3: 511-514, 1994.
165. Taioli, E., Trachman, J., Chen, X., Toniolo, P., and Garte, S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res., 55: 3757-3758, 1995.
166. Ishibe, N., Hankinson, S. E., Colditz, G. A., Spiegelman, D., Willett, W. C., Speizer, F. E., Kelsey, K. T., and Hunter, D. J. Cigarette smoking, cytoehrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res., 58: 667-671, 1998.
167. Moysich, K. B., Shields, P. G., Freudenheim, J. L., Schisterman, E. F., Vena, J. E., Kostyniak, P., Greizerstein, H., Marshall, J. R., Graham, S., and Ambrosone, C. B. Polychlorinated biphenyls, cytoehrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol. Biomark. Prev. 8: 41-44, 1999.
168. Buchert, E. T., Woosley, R. L., Swain, S. M., Oliver, S. J., Coughlin, S. S., Pickle, L., Trock, B., and Riegel, A. T. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics, 3: 322-327, 1993.
169. Ladona, M. G., Abildua, R. E., Ladero, J. M., Roman, J. M., Plaza, M. A., Agundez, J. A., Munoz, J. J., and Benitez, J. CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett., 99: 23-28, 1996.
170. Shields, P. G., Ambrosone, C. B., Graham, S., Bowman, E. D., Harrington, A. M., Gillenwater, K. A., Marshall, J. R., Vena, J. E., Laughlin, R., Nemoto, T., and Freudenheim, J. L. A cytoehrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer. Mol. Carcinog., 17: 144-150, 1996.
171. Feigelson, H. S., Coetzee, G. A., Kolonel, L. N., Ross, R. K., and Henderson, B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57: 1063-1065, 1997.
172. Dunning, A. M., Healey, C. S., Pharoah, P. D., Foster, N. A., Lipscombe, J. M., Redman, K. L., Easton, D. F., Day, N. E., and Ponder, B. A. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br. J. Cancer, 77: 2045-2047, 1998.
173. Helzlsouer, K. J., Harris, E. L., Parshad, R . Perry, H. R., Price, F. M., and Sanford, K. K. DNA repair proficiency: potential susceptibility factor for breast cancer. J. Natl. Cancer Inst., 88: 754-755, 1996.
174. Western, A., Pan, C. F., Bleiweiss, I. J., Ksieski, H. B., Roy, N., Maloney, N., and Wolff, M. S. CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 941-944, 1998.
175. Haiman, C. A., Hankinson, S. E., Spiegelman, D., Colditz, G. A., Willett, W. C., Speizer, F. E., Kelsey, K. T., and Hunter, D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59: 1015-1020, 1999.
176. Kristensen, V. N., Andersen, T. I., Lindblom, A., Erikstein, B., Magnus, P., and Borresen Dale, A. L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics, 8: 43-48, 1998.
177. Siegelmann Danieli, N., and Buetow, K. H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer, 79: 456-463, 1999.
178. Schoket, B., Philips, D. H., Poirier, M. C., Kostic, S., and Vincze, I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 and GSTM1 genotypes in lung patients. Carcinogenesis (Lond.), 19: 841-846, 1998.
179. Ichiba, M., Hagmar, L., Rannug, A., Högstedt, B., Alexandrie, A-K., Carstensen, U., and Hemminki, K. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYP1A1 and GSTM1 in chimney sweeps. Carcinogenesis (Lond.), 15: 1347-1352, 1994.
180. Rojas, M. Cascorbi, I., Alexandrov, K., Kriek, E., Auburtin, G., Mayer, L., Koop-Schneider, A., Roots, I., and Bartsch, H. Modulation of benzo(a)pyrene diolepoxide-DNA adducts in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis, 21: in press, 2000.
181. Butkiewicz, D., Grzybowska, E., Hemminki, H., Øvrebø, S., Haugen, A., Motykiewicz, G., and Chorazy, M. Modulation of DNA adduct levels in human mononuclear white blood cells and granulocytes by CYP1A1, CYP2D6 and GSTM1 genetic polymorphisms. Mutat. Res., 415: 97-108, 1998.
182. Ichiba, M., Wang, Y. P., Oishi, H., Zhang, J. S., Iyadomi, M., Minagawa, M., and Tomokuni, K. Lymphocytes, DNA adducts and genetic polymorphism for metabolic enzymes in low dose cigarette smokers. Biomarkers, 3: 63-71, 1998.
183. Pastorelli, R., Guanci, M., Cerri, A., Negri, E., La Vecchia, C., Fumagalli, F., Mezzetti, M., Cappelli, R., Panigalli, T., Fanelli, R., and Airoldt, L. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo-(a)pyrene-diolepoxide. Cancer Epidemiol. Biomark. Prev., 7: 703-709, 1998.